Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985660 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00985660 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 78 participants.
The verdict
NCT00985660, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.
Interventions
- DRUG Nisoldipine Extended-release Tablets, 30 mg
- DRUG Sular® Extended Release Tablets, 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00985660
The ClinicalTrials.gov registry entry for NCT00985660 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nisoldipine Extended-release Tablets, 30 mg is the first listed.
NCT00985660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00985660 about?
NCT00985660 is a clinical study titled "Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg". The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy ...
What is the current status of trial NCT00985660?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2007-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00985660?
The interventions under investigation include: Nisoldipine Extended-release Tablets, 30 mg (DRUG), Sular® Extended Release Tablets, 30 mg (DRUG).
Who is sponsoring clinical trial NCT00985660?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.